Gufic Biosciences secures NMPA approval to market Prilocaine (API) in China
Gufic Biosciences has received approval from the National Medical Products Administration (NMPA) in China for its product, Prilocaine (API), an amide-type local anesthetic. The approval ... Read More
Innovent Biologics’ olverembatinib gets Chinese breakthrough therapy status in SDH-deficient GIST
Innovent Biologics has been granted breakthrough therapy designation (BTD) for olverembatinib from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). ... Read More
AstraZeneca’s Forxiga wins approval in China for heart failure treatment
AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration (NMPA) to reduce the risk of cardiovascular ... Read More
Amgen secures breakthrough therapy designation for sotorasib in China
Amgen has achieved a major milestone in the global development of its investigational KRAS G12C inhibitor, sotorasib, with the National Medical Products Administration (NMPA) in ... Read More
Antengene receives approval for ATG-016 clinical trial in myelodysplastic syndrome
Antengene, a leading Chinese biopharmaceutical company, has announced a significant milestone with the approval of its Phase 1/2 clinical trial for ATG-016 (eltanexor) in the ... Read More